Global Influenza Vaccine Market

Influenza Vaccine Market Size, Share, Growth Analysis, By Vaccine Type (Quadrivalent, Trivalent), By Vaccine Formulation (Inactivated, Live Attenuated), By Technology, By Route of Administration, By Age Group, By Distribution Channel, By Region - Industry Forecast 2026-2033

Report ID: SQMIG35B2144 | Region: Global | Published Date: December, 2025
Pages: 200 |Tables: 114 |Figures: 77

To request a free sample copy of this report, please complete the form below.

Our Clients

  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt
  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt

    • FAQs

    Global Influenza Vaccine Market size was valued at USD 7.91 Billion in 2024 and is poised to grow from USD 8.46 Billion in 2025 to USD 14.52 Billion by 2033, growing at a CAGR of 6.98% during the forecast period (2026–2033).

    Companies are trying to expand their product pipelines by submitting new molecule applications or expanding the application of current molecules. Other strategies, including as mergers and acquisitions, industry-academia partnership to commercialize more marketed molecules, or sequencing approaches, will also have an impact on current market trends. The research also outlines company-specific product development strategies, market consolidation initiatives, and analyses of their individual strengths, weaknesses, opportunities, and threats. 'Sanofi Pasteur (France)', 'GlaxoSmithKline plc (GSK, UK)', 'Seqirus (CSL, Australia)', 'Pfizer Inc. (USA)', 'AstraZeneca PLC (UK)', 'Novavax, Inc. (USA)', 'Bharat Biotech (India)', 'Johnson & Johnson (USA)', 'Sinovac Biotech (China)', 'Bio Farma (Indonesia)', 'Serum Institute of India (India)', 'Abbott Biologicals B.V. (Netherlands)', 'Adimmune Corporation (Taiwan)', 'BIKEN Co., Ltd. (Japan)', 'Changchun BCHT Biotechnology (China)', 'Valneva SE (France)', 'Scinai Immunotherapeutics Ltd (Israel)', 'Moderna, Inc. (US)', 'Altimmune, Inc. (USA)', 'Osivax (France)'

    The increasing government support and surveillance for influenza vaccination is one of the critical and significant factors driving the global market. Surveillance at the national and global levels is required to monitor the supply, distribution, and administration of flu vaccines. WHO, in collaboration with other governments, constantly monitors demand and conducts immunization programmes around the world to reduce the vaccine's requirement in the region. For instance, in year 2021, the Australia government has already vaccinated approximately 5 million people through this immunization programme, and more than 20 million vaccines are still available.

    The coronavirus pandemic had an unforeseen impact on routine immunization programmes and campaigns in both developing and developed countries. However, flu vaccination rates have increased significantly during the pandemic due to factors such as increased pressure from health experts/health departments, as well as the extension/expansion of various government programmes that provide free flu vaccination.

    In 2021, North America dominated the influenza vaccine market and is anticipated to maintain its dominance throughout the forecast period. Rapid product launches, combined with technologically advanced vaccine manufacturing systems across the region, are expected to drive market growth in the region. Furthermore, rising influenza prevalence and high vaccine sales are expected to fuel market growth in North America. Furthermore, rising government funding, the presence of strong key players, and sophisticated vaccination centres and hospitals will all contribute to the market's stellar growth.

    Related Reports

    Avian Influenza Vaccine Market
    Buy Now GET FREE SAMPLE
    Influenza Diagnostics Market
    Buy Now GET FREE SAMPLE
    Therapeutic Vaccines Market
    Buy Now GET FREE SAMPLE
    Digital Vaccine Market
    Buy Now GET FREE SAMPLE
    Cholera Vaccines Market
    Buy Now GET FREE SAMPLE
    Vaccine Adjuvants Market
    Buy Now GET FREE SAMPLE
    Recombinant Vaccines Market
    Buy Now GET FREE SAMPLE
    Vaccine Delivery Devices Market
    Buy Now GET FREE SAMPLE

    Feedback From Our Clients

    Global Influenza Vaccine Market

    Report ID: SQMIG35B2144

    $5,300
    BUY NOW